| Literature DB >> 28814301 |
Eva Maria Gudmundsdottir1, Jon Hrafnkelsson2, Vilhjalmur Rafnsson3.
Abstract
BACKGROUND: To evaluate cancer incidence among licenced commercial pilots in association with cosmic radiation.Entities:
Keywords: Aircrew; Basal cell carcinoma of skin; Cancer registry; Cosmic radiation; Malignant melanoma; Prostate cancer
Mesh:
Year: 2017 PMID: 28814301 PMCID: PMC5559846 DOI: 10.1186/s12940-017-0295-4
Source DB: PubMed Journal: Environ Health ISSN: 1476-069X Impact factor: 5.984
Summary characteristics
| Icelandair pilots | Other pilots | All pilots | |
|---|---|---|---|
| Number | 286 | 265 | 551 |
| Person-years | 8514 | 8993 | 17,507 |
| Year of birth, median (range) | 1959 (1922–1978) | 1946 (1901–1979) | 1951 |
| Year of license, median (range) | 1987 (1944–2000) | 1970 (1935–2004) | 1977 |
| Years of employment, median (range) | 16 (1–43) | NA | NA |
| Cumulative air hours, median (range) | 7961 (58–29,966) | NA | NA |
| Cumulative mSv, median (range) | 22.55 (0.28–83.20) | NA | NA |
| Cumulative mSv up to age of 40 years, median (range) | 5.80 (0–17.17) | NA | NA |
Abbreviations: MilliSievert (mSv), and not available (NA)
Observed and expected number of cancers, standardized incidence ratios, and confidence intervals among all pilots
| Cancer site (ICD-10) | Obs | Exp | SIR | (95% CI) |
|---|---|---|---|---|
| All (C00-C97, D09-D47a) | 83 | 92.49 | 0.90 | 0.71 to 1.11 |
| Oesophagus (C15) | 2 | 1.73 | 1.16 | 0.13 to 4.18 |
| Stomach (C16) | 3 | 3.96 | 0.76 | 0.15 to 2.21 |
| Colon and rectum (C18, C20) | 7 | 9.18 | 0.76 | 0.31 to 1.57 |
| Gallbladder (C23) | 1 | 0.10 | 10.15 | 0.13 to 56.46 |
| Larynx (C32) | 1 | 0.85 | 1.17 | 0.02 to 6.52 |
| Bronchus and lung (C33, C34) | 5 | 10.88 | 0.46 | 0.15 to 1.07 |
| Bone (C41) | 2 | 0.09 | 22.45 | 2.52 to 81.06 |
| melanoma (C43) | 7 | 2.12 | 3.31 | 1.33 to 6.81 |
| Other skin cancer (C44) | 4 | 3.75 | 1.07 | 0.29 to 2.73 |
| Penis (C60) | 1 | 0.31 | 3.18 | 0.42 to 17.72 |
| Prostate (C61) | 28 | 24.92 | 1.12 | 0.75 to 1.62 |
| Kidney (C64) | 5 | 4.22 | 1.18 | 0.40 to 2.92 |
| Bladder (C67) | 4 | 6.55 | 0.61 | 0.16 to 1.56 |
| Eye (C69) | 1 | 0.25 | 3.95 | 0.05 to 21.97 |
| Brain (C71, D33) | 4 | 1.69 | 2.37 | 0.64 to 6.06 |
| Thyroid gland (C73) | 3 | 1.41 | 2.13 | 0.43 to 6.23 |
| Cancer without specification of site (C80) | 3 | 1.62 | 1.85 | 0.37 to 5.40 |
| Mature T/NK-cell lymphomas (C84.6) | 1 | 0.32 | 3.13 | 0.04 to 17.43 |
| Chronic lymphocytic leukaemia of B-cell type (C91.1) | 1 | 0.94 | 1.06 | 0.01 to 5.91 |
| Acute myeloid leukaemia (C92.0) | 1 | 0.64 | 1.56 | 0.02 to 8.69 |
| Not included in all cancers: | ||||
| Basal cell carcinoma of the skin (C44) | 31 | 12.44 | 2.49 | 1.69 to 3.54 |
Abbreviations: International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10), observed (Obs), expected (Exp), standardized incidence ratio (SIR), and confidence interval (CI)
aRelated to brain: D09, D30, D35, D41, D32–33, D42–43, D44 and D46–47
Observed and expected number of cancers, SIR and 95% CI among Icelandair pilots and other pilots
| Icelandair pilots | Other pilots | |||||||
|---|---|---|---|---|---|---|---|---|
| Cancer site (ICD-10) | Obs | Exp | SIR | 95% CI | Obs | Exp | SIR | 95% CI |
| All (C00-C97, D09-D47a) | 46 | 43.23 | 1.06 | 0.78 to 1.42 | 37 | 49.26 | 0.75 | 0.53 to 1.04 |
| Oesophagus (C15) | 1 | 0.78 | 1.29 | 0.02 to 7.17 | 1 | 0.95 | 1.05 | 0.01 to 5.86 |
| Stomach (C16) | 1 | 1.55 | 0.64 | 0.01 to 3.58 | 2 | 2.40 | 0.83 | 0.09 to 3.00 |
| Colon and rectum (C18, C20) | 3 | 4.24 | 0.71 | 0.14 to 2.07 | 4 | 4.94 | 0.81 | 0.22 to 2.07 |
| Gallbladder (C23) | 0 | 0.04 | - | 0.00 to 90.97 | 1 | 0.06 | 17.18 | 0.22 to 95.57 |
| Larynx (C32) | 0 | 0.37 | - | 0.00 to 9.81 | 1 | 0.48 | 2.09 | 0.03 to 11.61 |
| Bronchus and lung (C33, C34) | 2 | 5.10 | 0.39 | 0.04 to 1.42 | 3 | 5.78 | 0.52 | 0.10 to 1.52 |
| Bone (C41) | 1 | 0.04 | 24.63 | 0.32 to 137.00 | 1 | 0.05 | 20.63 | 0.27 to 114.80 |
| Melanoma (C43) | 6 | 1.10 | 5.48 | 2.00 to 11.92 | 1 | 1.02 | 0.98 | 0.01 to 5.45 |
| Other skin cancer (C44) | 4 | 1.79 | 2.23 | 0.60 to 5.71 | 0 | 1.96 | - | 0.00 to 1.87 |
| Penis (C60) | 0 | 0.14 | - | 0.00 to 25.37 | 1 | 0.17 | 5.90 | 0.08 to 32.82 |
| Prostate (C61) | 15 | 11.78 | 1.27 | 0.71 to 2.10 | 13 | 13.14 | 0.99 | 0.53 to 1.69 |
| Kidney (C64) | 5 | 1.99 | 2.51 | 0.81 to 5.86 | 0 | 2.23 | - | 0.00 to 1.64 |
| Bladder (C67) | 0 | 3.03 | - | 0.00 to 1.21 | 4 | 3.53 | 1.13 | 0.31 to 2.90 |
| Eye (C69) | 1 | 0.12 | 8.27 | 0.11 to 46.01 | 0 | 0.13 | - | 0.00 to 27.72 |
| Brain (C71, D33) | 0 | 0.82 | - | 0.00 to 4.48 | 4 | 0.87 | 4.60 | 1.24 to 11.77 |
| Thyroid gland (C73) | 3 | 0.68 | 4.44 | 0.89 to 12.97 | 0 | 0.73 | - | 0.00 to 5.01 |
| Cancer w/o specification of site (C80) | 1 | 0.74 | 1.35 | 0.02 to 7.51 | 2 | 0.88 | 2.27 | 0.25 to 8.19 |
| Mature T/NK-cell lymphomas (C84.6) | 1 | 0.16 | 6.07 | 0.08 to 33.77 | 0 | 0.15 | - | 0.00 to 23.74 |
| Chronic lymphocytic leukaemia (C91.1) | 1 | 0.43 | 2.30 | 0.03 to 12.80 | 0 | 0.51 | - | 0.00 to 7.25 |
| Acute myeloid leukaemia (C92.0) | 1 | 0.30 | 3.39 | 0.04 to 18.84 | 0 | 0.35 | - | 0.00 to 10.63 |
| Not included in all cancers: | ||||||||
| Basal cell carcinoma of the skin (C44) | 22 | 6.21 | 3.54 | 2.22 to 5.37 | 9 | 6.23 | 1.44 | 0.66 to 2.74 |
Abbreviations: International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10), observed (Obs), expected (Exp), standardized incidence ratio (SIR), and confidence interval (CI).
aRelated to brain: D09, D30, D35, D41, D32–33, D42–43, D44 and D46–47
Age adjusted relative risk for all cancers, prostate cancer and malignant melanoma, by employment years, cumulative air hours, cumulative mSv, and cumulative mSv up to age of 40 years
| All primary cancers (C00-C97) | Prostate cancer (C61) | Malignant melanoma (C43) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Exposure | No | Yes | No | Yes | No | Yes | |||
| metrics |
|
| RR (95% CI) |
|
| RR (95% CI) |
|
| RR (95% CI) |
| Employment years | |||||||||
| Unexposed | 232 | 33 | 1.00 (Referent) | 253 | 12 | 1.00 (Referent) | 264 | 1 | 1.00 (Referent) |
| <15 | 127 | 5 | 1.73 (0.51 to 5.18) | 132 | 0 | − | 131 | 1 | 9.33 (0.22 to 596.01) |
| 15+ | 115 | 39 | 2.34 (1.45 to 3.80) | 139 | 15 | 2.40 (1.10 to 5.23) | 149 | 5 | 9.55 (1.49 to 187.47) |
| p-trend | 0.002 | 0.05 | 0.02 | ||||||
| Cumulative air hours | |||||||||
| Unexposed | 232 | 33 | 1.00 (Referent) | 253 | 12 | 1.00 (Referent) | 264 | 1 | 1.00 (Referent) |
| <10,000 | 163 | 7 | 1.40 (0.49 to 3.73) | 170 | 0 | − | 169 | 1 | 3.27 (0.09 to 160.46) |
| 10,000+ | 79 | 37 | 2.41 (1.50 to 3.90) | 101 | 15 | 2.61 (1.22 to 5.60) | 111 | 5 | 10.29 (1.66 to 197.12) |
| p-trend | 0.0001 | 0.01 | 0.004 | ||||||
| Cumulative mSv | |||||||||
| Unexposed | 232 | 33 | 1.00 (Referent) | 253 | 12 | 1.00 (Referent) | 264 | 1 | 1.00 (Referent) |
| <25 | 145 | 6 | 1.36 (0.46 to 3.56) | 151 | 0 | − | 150 | 1 | 5.07 (0.14 to 201.23) |
| 25+ | 97 | 38 | 2.42 (1.50 to 3.92) | 120 | 15 | 2.57 (1.18 to 5.56) | 130 | 5 | 9.88 (1.57 to 190.78) |
| p-trend | 0.0005 | 0.02 | 0.009 | ||||||
| Cumulative mSv up to age of 40 years | |||||||||
| Unexposed | 232 | 33 | 1.00 (Referent) | 253 | 12 | 1.00 (Referent) | 264 | 1 | 1.00 (Referent) |
| <5 | 120 | 5 | 1.53 (0.47 to 4.20) | 125 | 0 | − | 125 | 0 | − |
| 5+ | 122 | 39 | 2.37 (1.47 to 3.85) | 146 | 15 | 2.47 (1.13 to 5.41) | 155 | 6 | 10.34 (1.23 to 86.61) |
| p-trend | 0.003 | 0.06 | 0.005 | ||||||
Abbreviations: MilliSievert (mSv), relative risk (RR), confidence interval (CI)
Age adjusted relative risk for BCC, all and of trunk, by employment years, cumulative air hours, cumulative mSv, and cumulative mSv up to age of 40 years
| Basal cell carcinoma of skin, all (C44)a | Basal cell carcinoma of skin, of trunk (C44)a | |||||
|---|---|---|---|---|---|---|
| Exposure | No | Yes | No | Yes | ||
| metrics |
|
| RR (95% CI) |
|
| RR (95% CI) |
| Employment years | ||||||
| Unexposed | 256 | 9 | 1.00 (Referent) | 263 | 2 | 1.00 (Referent) |
| <15 | 127 | 5 | 2.95 (0.70 to 12.74) | 130 | 2 | 4.29 (0.35 to 65.08) |
| 15+ | 137 | 17 | 3.34 (1.51 to 7.89) | 147 | 7 | 6.07 (1.46 to 40.86) |
| p-trend | 0.002 | 0.01 | ||||
| Cumulative air hours | ||||||
| Unexposed | 232 | 33 | 1.00 (Referent) | 253 | 12 | 1.00 (Referent) |
| <10,000 | 163 | 7 | 1.40 (0.49 to 3.73) | 170 | 0 | − |
| 10,000+ | 79 | 37 | 2.41 (1.50 to 3.90) | 101 | 15 | 2.61 (1.22 to 5.60) |
| p-trend | 0.0003 | 0.002 | ||||
| Cumulative mSv | ||||||
| Unexposed | 256 | 9 | 1.00 (Referent) | 263 | 2 | 1.00 (Referent) |
| <25 | 146 | 5 | 1.92 (0.49 to 7.23) | 149 | 2 | 2.75 (0.25 to 33.24) |
| 25+ | 118 | 17 | 3.61 (1.64 to 8.48) | 128 | 7 | 6.65 (1.61 to 44.64) |
| p-trend | 0.0005 | 0.005 | ||||
| Cumulative mSv up to age of 40 years | ||||||
| Unexposed | 256 | 9 | 1.00 (Referent) | 263 | 2 | 1.00 (Referent) |
| <5 | 122 | 3 | 1.37 (0.27 to 5.74) | 123 | 2 | 4.51 (0.40 to 54.67) |
| 5+ | 142 | 19 | 3.62 (1.68 to 8.45) | 154 | 7 | 6.08 (1.46 to 41.06) |
| p-trend | 0.0006 | 0.01 | ||||
Abbreviations: MilliSievert (mSv), relative risk (RR), confidence interval (CI)
aNot included in all cancers
Location of the three main histological types of skin cancers among Icelandair pilots and other pilots
| Malignant | Squamous | Basal cell | |
|---|---|---|---|
| Location | melanoma (C43) | cell carcinoma (C44) | carcinoma (C44) |
| Icelandair pilots | |||
| Total | 6 | 4 | 22 |
| Trunk | 3 | 1 | 9 |
| Limbs | 2 | - | 2 |
| Unspecified | - | - | 1 |
| Head and neck | 1 | 3 | 10 |
| Other pilots | |||
| Total | 1 | - | 9 |
| Trunk | - | - | 2 |
| Limbs | 1 | - | - |
| Unspecified | - | - | - |
| Head and neck | - | - | 7 |